Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.

@article{Ryn2014ReversalOD,
  title={Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.},
  author={Joanne van Ryn and Johanna Schurer and Monika Kink-Eiband and Andreas Clemens},
  journal={Anesthesiology},
  year={2014},
  volume={120 6},
  pages={1429-40}
}
BACKGROUND Dabigatran is a potent oral anticoagulant. Like any anticoagulant, there is an increased risk of bleeding associated with its use, and reversal may be needed in cases of severe bleeding. METHODS In this study, six coagulation factor concentrates (CFCs) were tested for their ability to reduce bleeding induced by oral dabigatran etexilate (30 mg/kg) in a rat-tail bleeding model (n = 5 to 8 per group): three-factor (Profilnine [Grifols Biologicals Inc., Los Angeles, CA] and Bebulin… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
20 Extracted Citations
45 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 20 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 45 references

In vitro assessment , using thrombin generation , of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban

  • AC Martin, B LeBonniec, +4 authors A Godier
  • Thromb Haemost
  • 2013

Similar Papers

Loading similar papers…